Samsung on course to produce Moderna vaccine: CEO
Samsung Biologics CEO John Rim, left, and Moderna CEO Stephane Bancel, exchange agreements during a vaccine partnership event at a hotel in Washington, D.C., May 22, with President Moon Jae-in in attendance. YonhapBy Baek Byung-yeulSamsung Biologics is on course to manufacture U.S. biotech firm Moderna's COVID-19 vaccine, its CEO John Rim said, highlighting the global bio industry's efforts in the battle against the pandemic.“As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna's mRNA-1273 vaccine with quality, speed and efficiency to aid in the fight against this global crisis,” Rim said during the BIO Digital event online, Tuesday.BIO Digital is a virtual version of the BIO International Convention, a major trading conference in the biotech industry. Samsung has taken part in the annual event since its establishment in 2011 and has met with its clients online since the conference was converted to a virtual format last year due to the COVID-19 pandemic. This year's
